Paysign Q3 revenue beats on patient affordability programs

By Reuters News


Overview

  • U.S. patient affordability and plasma payments firm's Q3 2026 revenue rose 43%, beating analyst expectations

  • Gross margin expanded to 64.7%, driven by growth in patient affordability programs

  • Company raised full-year guidance for gross margin, net income, EPS, and adjusted EBITDA


Outlook

  • Paysign sees 2026 revenue at $114.0 mln to $117.0 mln

  • Company raises 2026 guidance for gross margin, net income, GAAP EPS and adjusted EBITDA

  • Paysign expects to exit 2026 with 190-195 patient affordability programs and 445-450 plasma centers


Result Drivers

  • PATIENT AFFORDABILITY GROWTH - Co said revenue surge was driven by expansion of patient affordability programs and higher revenue per program

  • MIX SHIFT - Higher share of pharma revenue contributed to margin expansion

  • PLASMA UTILIZATION - Higher average revenue per plasma center offset impact of declining center count


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$30.80 mln

$29.02 mln (5 Analysts)

Q3 Net Income

$6.74 mln

Q3 Gross Margin

64.70%


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the business support services peer group is "buy"

  • Wall Street's median 12-month price target for Paysign Inc is $15.00, about 2.1% above its November 6 closing price of $14.69

  • The stock recently traded at 36 times the next 12-month earnings vs. a P/E of 32 three months ago


Reuters Recommended Reads

  • Nov 9 - Lincoln Educational Q3 revenue rises 13%, beats estimates

  • Nov 9 - Israel's Kamada Q3 revenue up 11%, raises forecast

  • Nov 9 - Biopharma Almirall 9M sales rise on European dermatology growth


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.